Today: 11 June 2026
JPMorgan Stock Price Targets Reset as Evercore Cuts to $320, Piper Holds Overweight
6 April 2026
1 min read

JPMorgan Stock Price Targets Reset as Evercore Cuts to $320, Piper Holds Overweight

NEW YORK, April 6, 2026, 12:14 PM EDT

JPMorgan Chase saw its price target slashed by Evercore ISI on Monday, with analysts trimming the outlook to $320 from $350. They’re sticking with an Outperform, signaling continued optimism versus the sector. Shares changed hands at $296.06 midday in New York.

These calls draw attention ahead of JPMorgan’s first-quarter results on April 14, a date that tends to set the tone for the rest of the big banks. On one hand, investors see evidence of solid trading and investment-banking fees. On the other, a $105 billion expense plan is fueling ongoing scrutiny of spending.

Monday’s math got trickier after CEO Jamie Dimon, through his annual letter to shareholders, flagged “significant” challenges ahead. He cautioned that the war in Iran might trigger oil and commodity shocks, more persistent inflation, and higher interest rates than markets anticipate. JPMorgan Chase

Wall Street’s opinions are still far from aligned. On Monday, Goldman Sachs bumped its target up to $365 from $352, sticking with its Buy call. Autonomous went the other direction, trimming its target down to $324 from $360 and holding Neutral. Piper Sandler last week kept its Overweight rating, but sliced the target to $325 from $345. MarketBeat data, for its part, shows a broader consensus tilting Moderate Buy, with the average target just over $334.

JPMorgan’s latest numbers say a lot about why certain analysts are still buyers here. The bank’s 2025 annual report, out Monday, shows revenue hit a record for the eighth year running—$185.6 billion on the top line, net income at $57.0 billion. This comes after it topped fourth-quarter profit forecasts back in January.

Executives say the recent burst of spending is finally beginning to deliver results. At the February investor day, co-CEO Doug Petno pointed to “powerful strategic drivers” still pushing mergers and acquisitions, while CFO Jeremy Barnum highlighted “tangible benefits” from the company’s AI investments. Consumer chief Marianne Lake kept it simple: “everything is solid” with consumers. UBS analyst Erika Najarian noted investors were “very keen” for details on how AI could actually lift productivity and revenue, as JPMorgan readies a $19.8 billion tech budget for this year. Reuters

Not all estimates headed in lockstep. On April 2, a Simply Wall St community post said it cut its model-driven fair value for JPMorgan down to $337.75 from $344.78. The reason: a lower multiple on future earnings, even as long-term growth assumptions ticked up. So JPMorgan’s price target now spans from fresh low-$320s forecasts to Goldman’s $365 mark.

The danger: there’s less room for slip-ups now. Should M&A slow, loan losses climb, or all the tech and branch outlays fall short on returns, analysts might slash forecasts again. Dimon’s latest alerts on global tensions and price pressures only sharpen the risk for a bank that — as of its February investor day — still topped Bank of America and Citigroup’s combined valuations.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Palantir Stock (PLTR) Splits Opinion as Bulls Eye $1 Trillion and Bears Warn of Sub-$100 Drop
Previous Story

Palantir Stock (PLTR) Splits Opinion as Bulls Eye $1 Trillion and Bears Warn of Sub-$100 Drop

Dow Jones Today: Industrial Average Rises as Iran Ceasefire Hopes Offset Oil and Fed Fears
Next Story

Dow Jones Today: Industrial Average Rises as Iran Ceasefire Hopes Offset Oil and Fed Fears

Go toTop